Recent Updates
Recently added Catalysts
NKTX Positive Sentiment

Nkarta to Participate at Upcoming Investor Conferences

Tuesday, November 7, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Nkarta, Inc. has announced its participation in two upcoming investor conferences, the Stifel Healthcare Conference and the Evercore ISI HealthCONx Conference. Both events will feature fireside chats and offer a platform for Nkarta to discuss its engineered natural killer (NK) cell therapies. A webcast of these events will be available on Nkarta's website, providing broad access for interested parties. This engagement highlights Nkarta's advancements in developing innovative biopharmaceutical treatments.
Price reaction · baseline $2.33 (2023-11-06 close) · hit after-hours · 1 other NKTX headline(s) in the window, move may be shared
day 0 close · peak
-1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in multiple investor conferences boosts visibility.
  • Showcases Nkarta's advancements in NK cell therapies.
  • Opportunity to engage with investors and stakeholders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+124%
120-day peak, hindsight
Typical move
7.6%
average across 3 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
NKX101- CAR NK cell therapy
Phase 1 · Relapsed/Refractory AML

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation at two upcoming investor conferences:
Stifel Healthcare Conference
10:55 a.m. ET – fireside chat
Evercore ISI HealthCONx Conference
12:30 p.m. ET – fireside chat
A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:

Frequently Asked Questions

What type of therapies does Nkarta develop?

Nkarta develops engineered natural killer (NK) cell therapies.

When is Nkarta participating in the Stifel Healthcare Conference?

Nkarta's fireside chat at the Stifel Healthcare Conference is at 10:55 a.m. ET.

Where can I watch Nkarta's investor conference webcasts?

Webcasts of the conferences will be available on Nkarta’s website.

What is CRISPR's role in Nkarta's therapies?

CRISPR is used in Nkarta's proprietary genome engineering technologies.

How long will the conference replays be available?

The conference replays will be archived on the website for about 90 days.

ShareAdd on Google
Tags: NKTX Viatris Investor Conferences Healthcare NK cell therapies Nkarta investor conferences biopharmaceuticals Nasdaq NKTX
Last updated: Nov 7, 2023

Biotech snapshot

Cash runway
$183M liquidity · $8M/mo burn
~22 mo
Low dilution risk
Lead asset
NKX101- CAR NK cell therapyPhase 1
Relapsed/Refractory AML →

Catalyst track record

+124%
best trade around NKTX's last catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for NKTX.

See every catalyst's timing & PoA →